Ebumab Holding ApS: Financial statements 2022
CVR: 39807556
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Ebumab Holding ApS (CVR 39807556) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -56,679 and a net result of DKK 100,146 compared with DKK 163,253 the year before. Equity in the 2022 report amounted to DKK 5,473,116. The solvency ratio was 98.1%.
- Revenue
- DKK 0
- Gross Profit
- DKK -56,679
- Profit/Loss
- DKK 100,146
- Equity
- DKK 5,473,116
- Total Assets
- DKK 5,579,096
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 0 | -57K | 100K | 5.5M | 0 |
| 2021 | 0 | -45K | 163K | 5.4M | 0 |
| 2020 | 785K | 392K | -337K | 5.2M | 1 |
Official annual report
Keep an eye on Ebumab Holding ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Ebumab Holding ApS has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK 163,253.
About Ebumab Holding ApS
Ebumab Holding ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Ikke-finansielle hovedsæders aktiviteter. The management consists of Hans Heugh Wandall and Johan Henrik Faber. The board consists of Hans Heugh Wandall (chair), Johan Henrik Faber, Mads Nikolaj Behrndt-Eriksen and Søren Erik Bjørn. The company's owners include Wandall Holding ApS, Johan H. Faber ApS and Batchelor Holding ApS. The company has 1 employee (2024). In 2025, the company reported a gross profit of DKK -86,871 and a net result of DKK 75,634,949 compared with DKK -39,197 the year before. Equity in the 2025 report amounted to DKK 5,684,083.